Finance Foggle

FDA Approves Breakthrough Eye Drops That Fix Near Vision Without Glasses Key Takeaways Aspect Details Latest FDA Approval VIZZ eye drops approved July 2025, works up to 10 hours Active Ingredient Aceclidine 1.44% - first of its kind in the US How Long It Works Up to 10 hours per dose with once-daily application Effectiveness 71% of users gained 3+ lines of near vision improvement Availability Expected launch between October-December 2025 Other Options Vuity (pilocarpine) and QLOSI also FDA-approved Who Can Use It Adults with presbyopia (age-related near vision loss) Cost Coverage Insurance coverage varies, prescription required What Are These Revolutionary Eye Drops? The FDA just approved VIZZ, the first and only aceclidine-based eye drop for treating presbyopia, marking a global first in this treatment category. This isn't your grandfather's reading glasses solution - we're talking about drops that can give you clear near vision for up to 10 hours with just one d...

  Key Takeaways 🚨  FDA Warning Issued : The FDA sent WHOOP a warning letter on July 14, 2025, declaring its Blood Pressure Insights (BPI) feature an unapproved medical device . ⚖️  Regulatory Dispute : WHOOP argues BPI is a wellness tool (exempt from FDA review), while the FDA insists blood pressure measurement is inherently clinical . 💡  How BPI Works : Uses morning heart rate, HRV, and blood flow patterns (calibrated via a cuff) to estimate daily systolic/diastolic ranges, not real-time readings . ⚠️  FDA’s Safety Concerns : Inaccurate readings could delay hypertension treatment, risking stroke or heart failure . 💰  Consumer Impact : BPI is a key selling point of WHOOP’s $359/year “Life” tier. Removal could devalue the subscription . ⏳  Current Status : BPI remains active in the U.S. as WHOOP contests the FDA’s stance . The FDA-WHOOP Clash Over Blood Pressure Insights What’s Happening? On July 14, 2025, the FDA sent WHOOP a formal warning letter. ...